These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 16684875)
1. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs. Roth-Cline MD Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875 [No Abstract] [Full Text] [Related]
2. Evaluating drug effects in the post-Vioxx world: there must be a better way. Avorn J Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873 [No Abstract] [Full Text] [Related]
3. The Vioxx debacle. Fielder JH IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852 [No Abstract] [Full Text] [Related]
4. The Vioxx fallout. Palmer K Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592 [No Abstract] [Full Text] [Related]
5. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
6. How to avoid another 'Vioxx'. Frantz S Nat Rev Drug Discov; 2005 Jan; 4(1):5-7. PubMed ID: 15690595 [No Abstract] [Full Text] [Related]
10. The sad story of Vioxx, and what we should learn from it. Karha J; Topol EJ Cleve Clin J Med; 2004 Dec; 71(12):933-4, 936, 938-9. PubMed ID: 15641522 [No Abstract] [Full Text] [Related]
11. COX-2 inhibitors and the heart: putting risk in perspective. Bobadilla RV; Barnett EM; Randels CL Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003 [No Abstract] [Full Text] [Related]
12. COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Fendrick AM Am J Manag Care; 2004 Nov; 10(11 Pt 1):740-1. PubMed ID: 15623263 [No Abstract] [Full Text] [Related]
13. Observational studies and the withdrawal of rofecoxib. Watson DJ; Santanello NC Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998 [No Abstract] [Full Text] [Related]
14. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. Cahana A; Mauron A J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707 [No Abstract] [Full Text] [Related]
15. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Couzin J Science; 2004 Oct; 306(5695):384-5. PubMed ID: 15486258 [No Abstract] [Full Text] [Related]
16. [Rofecoxib (Vioxx) has been withdrawn, what next?]. Idänpään-Heikkilä JE; Klaukka T Duodecim; 2004; 120(21):2489-90. PubMed ID: 15631403 [No Abstract] [Full Text] [Related]
17. Anticipating a Vioxx defense strategy: will corporate honesty be enough? Willis KD Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567 [No Abstract] [Full Text] [Related]
18. The Vioxx debacle revisited. Good CB; Kelley CL Am J Med; 2005 Sep; 118(9):1055-6; author reply 1056-7. PubMed ID: 16164902 [No Abstract] [Full Text] [Related]
19. The lessons of Vioxx. Weinberg JM Cutis; 2005 Jan; 75(1):17. PubMed ID: 15732429 [No Abstract] [Full Text] [Related]
20. Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). Carné X; Cruz N Eur J Epidemiol; 2005; 20(2):127-9. PubMed ID: 15792277 [No Abstract] [Full Text] [Related] [Next] [New Search]